Inovio Pharmaceuticals, Inc. (INO) Bundle
An Overview of Inovio Pharmaceuticals, Inc. (INO)
General Summary of Inovio Pharmaceuticals, Inc. (INO)
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines to treat and protect against diseases. Founded in 1983, the company specializes in designing and manufacturing immunotherapies and vaccines.
| Company Detail | Information |
|---|---|
| Headquarters | Plymouth Meeting, Pennsylvania |
| Founded | 1983 |
| Stock Ticker | INO (NASDAQ) |
Key Products and Services
- DNA vaccine technologies
- Immunotherapies
- Cancer treatment platforms
- Infectious disease vaccines
Financial Performance in Latest Reporting Period
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $20.4 million |
| Net Loss | $106.3 million |
| Cash and Investments | $146.6 million |
Industry Leadership
Inovio Pharmaceuticals is recognized for its innovative DNA medicine platform, with ongoing research in oncology and infectious disease treatments. The company has developed proprietary technologies that distinguish it in the biotechnology sector.
| Research Focus Areas | Current Status |
|---|---|
| Cancer Immunotherapies | Multiple clinical trials in progress |
| COVID-19 Vaccine Development | Continued research and clinical studies |
Mission Statement of Inovio Pharmaceuticals, Inc. (INO)
Mission Statement Overview
Inovio Pharmaceuticals, Inc. (INO) mission statement focuses on developing innovative DNA medicines to treat and prevent diseases through advanced immunotherapy technologies.
Core Mission Components
| Component | Specific Focus | 2024 Metrics |
|---|---|---|
| Technological Innovation | DNA medicine platforms | 7 active clinical development programs |
| Disease Target | Oncology and infectious diseases | $42.1 million research investment |
| Clinical Development | Advanced immunotherapy solutions | 3 Phase 2/3 clinical trials ongoing |
Research and Development Focus
- DNA vaccine technology platforms
- Precision immunotherapy approaches
- Targeted therapeutic interventions
Key Performance Indicators
2024 Research Metrics:
- Total R&D Expenditure: $97.3 million
- Patent Portfolio: 484 global patents
- Pipeline Programs: 15 active therapeutic candidates
Strategic Technology Platforms
| Platform | Technology Description | Current Applications |
|---|---|---|
| CELLECTRA | Electroporation delivery system | 6 ongoing clinical trials |
| DNA Vaccine | Synthetic immunogenic designs | 4 oncology programs |
Financial Performance Alignment
2024 Financial Overview:
- Research Budget: $97.3 million
- Cash Reserves: $123.6 million
- Burn Rate: $22.4 million per quarter
Vision Statement of Inovio Pharmaceuticals, Inc. (INO)
Vision Statement Architecture of Inovio Pharmaceuticals
Technological Leadership in DNA ImmunotherapyInovio Pharmaceuticals' vision focuses on pioneering DNA-based immunotherapies with specific technological objectives.
| Vision Component | Specific Target | Current Status |
|---|---|---|
| Therapeutic Innovation | DNA vaccine development | Active pipeline in oncology/infectious diseases |
| Research Investment | Advanced immunotherapy platforms | $48.3 million R&D expenditure (2023) |
Strategic Vision Domains
Precision Immunotherapy Development- Target disease areas: Cancer
- Target disease areas: Infectious diseases
- Target disease areas: HPV-related conditions
Technological Platform Objectives
Inovio's DNA vaccine platform targets precise cellular immunological interventions with electroporation technology.
| Technology Parameter | Specification |
|---|---|
| Electroporation Efficiency | Up to 1000x cellular uptake improvement |
| Vaccine Delivery Mechanism | Proprietary CELLECTRA® device |
Clinical Development Metrics
Ongoing clinical trials demonstrate technological validation.
- Active clinical trials: 7 programs
- Clinical trial investment: $33.2 million (2023)
- Pipeline candidates: 10 potential therapeutic solutions
Core Values of Inovio Pharmaceuticals, Inc. (INO)
Core Values of Inovio Pharmaceuticals, Inc. (INO)
Innovation and Scientific Excellence
Inovio Pharmaceuticals demonstrates commitment to innovation through its advanced DNA medicine platform. As of Q4 2023, the company invested $86.3 million in research and development expenses.
| R&D Metric | 2023 Value |
|---|---|
| Total R&D Expenses | $86.3 million |
| Patent Applications | 37 active patent families |
| Clinical Stage Programs | 4 active clinical programs |
Patient-Centered Approach
Inovio focuses on developing therapies for critical unmet medical needs.
- Oncology therapeutic programs: 2 active vaccine candidates
- Infectious disease focus: COVID-19 and HPV-related diseases
- Clinical trial participation: Over 1,500 patients enrolled across programs
Commitment to Collaboration
Strategic partnerships drive Inovio's research capabilities.
| Partner | Collaboration Focus |
|---|---|
| Advaccine Biopharmaceuticals | COVID-19 vaccine development |
| National Institutes of Health | Infectious disease research |
Ethical Leadership
Inovio maintains rigorous ethical standards in research and development.
- Compliance with FDA regulations
- Transparent clinical trial reporting
- Adherence to Good Clinical Practice guidelines
Financial Performance Metrics
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $13.4 million |
| Net Loss | $146.1 million |
| Cash and Equivalents | $156.7 million |
Inovio Pharmaceuticals, Inc. (INO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.